Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider
- 11 July 2014
- journal article
- Published by Springer Nature in Osteoporosis International
- Vol. 25 (12) , 2721-2728
Abstract
This analysis investigated the persistence of teriparatide for treatment of osteoporosis in 829 patients according to gender and health care provider treated with teriparatide. This study showed that female patients were less persistent than males and those patients treated in the practices of orthopedic surgeons were more treatment persistent than patients treated in general practitioner (GP) practices. The optimal persistency of teriparatide (TPTD) is of the upmost importance to ensure fracture risk reduction and pain relief. Data reporting on gender-specific or health care provider-dependent differences on health care provider-dependent persistence is currently lacking. We analyzed a large dataset extracted from the Disease Analyzer database (IMS Health, Germany). Out of a dataset of 15 million patients, we identified patients with osteoporosis who received first-time teriparatide prescriptions from January 2005 to December 2012. All 829 patients (677 females and 152 males) were included in the study. The patients were treated by 214 general practitioners (GPs) and 143 orthopedic surgeons. After 18 months of follow-up, 39.5 % of the female and 34 % of the male patients discontinued their treatment (p = 0.0308). We found a significant difference in the discontinuation rate of patients treated by orthopedic surgeons (35.0 %) compared to patients treated by GPs (44.2 %) (p = 0.0445). Additionally, at the end of the 18 months of follow up, 39.4 % of female and 47.8 % of male patients were still on treatment. We found a highly significant decreased risk for treatment discontinuation in patients with fractures prior to treatment initiation compared to those without such fractures (hazard ratio (HR) 0.77; 95 % confidence interval (CI) 0.66–0.90). There was a significantly increased risk of treatment discontinuation for female patients (HR 1.38; 95 % CI 1.10–1.74) compared to male patients. In conclusion, female patients presented higher discontinuation rates of TPTD compared to males. Patients treated in the practices of orthopedic surgeons were more persistent than patients treated in GP practices. TPTD persistence in patients with osteoporosis is higher than with antiresorptives but is still suboptimal and needs to be improved to ensure fracture risk reductions comparable to randomized controlled trial (RCT) results.Keywords
This publication has 22 references indexed in Scilit:
- Gender differences in persistency to bisphosphonates in patients with metastatic breast and prostate cancerInt. Journal of Clinical Pharmacology and Therapeutics, 2014
- The Effect of Age, Sex Hormones, and Bone Turnover Markers on Calcaneal Quantitative Ultrasonometry in Healthy German MenJournal of Clinical Densitometry, 2013
- The Epidemiology of OsteoporosisDeutsches Ärzteblatt international, 2013
- Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysisBreast Cancer Research and Treatment, 2013
- Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort studyBMC Musculoskeletal Disorders, 2013
- Persistence and compliance of medications used in the treatment of osteoporosis – analysis using a large scale, representative, longitudinal German databaseInt. Journal of Clinical Pharmacology and Therapeutics, 2012
- Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insuranceOsteoporosis International, 2010
- Adherence and persistence in patients with severe osteoporosis treated with teriparatideCurrent Medical Research and Opinion, 2010
- Validity and representativeness of the “Disease Analyzer” patient database for use in pharmaco-epidemiological and pharmacoeconomic studiesInt. Journal of Clinical Pharmacology and Therapeutics, 2009
- Non-compliance: the Achilles' heel of anti-fracture efficacyOsteoporosis International, 2007